| 12 | 0 | 26 |
| 下载次数 | 被引频次 | 阅读次数 |
感染性疾病是造成儿童死亡最主要的原因之一，有效评估儿童感染性疾病的病情对改善其预后具有重大意义。目前临床常用的辅助检查包括病原学检测和C反应蛋白、降钙素原等血液学标志物检测，但病原学培养与鉴定耗时较长、部分血液学标志物的特异性不足。可溶性尿激酶型纤溶酶原激活物受体（soluble urokinase plasminogen activator receptor, suPAR）是一种新型生物标志物，为表达于多种免疫活化细胞表面的尿激酶型纤溶酶原激活物受体的可溶形式，在炎症或感染的过程中可反映机体免疫系统的激活程度，在多种儿童感染性疾病的早期诊断、病情评估及治疗监测等方面具有一定的应用价值。本文对suPAR在儿童肺部感染、疟疾、脓毒症、尿路感染及结核病等多种感染性疾病中的应用进展进行综述，并对未来可能的研究方向作出展望。
Abstract：Infectious diseases are one of the leading causes of childhood mortality, and effective evaluation of pediatric infectious diseases is crucial for improving their prognosis. Currently, commonly used clinical auxiliary examinations include etiological detection and hematological markers such as C-reactive protein and procalcitonin. However, etiological culture and identification require a considerable amount of time, and some hematological markers lack sufficient specificity. Soluble urokinase plasminogen activator receptor(suPAR) is a novel biomarker, representing the soluble form of the urokinase plasminogen activator receptor expressed on the surface of various immune-activated cells. It reflects the activation level of the body's immune system during inflammation or infection, and has certain practical value in the early diagnosis, disease assessment, and treatment monitoring of various pediatric infectious diseases. This article reviews the progress in the application of suPAR in various infectious diseases among children, including pulmonary infections, malaria, sepsis, urinary tract infections, and tuberculosis, and provides insights into possible future research directions.
[1]Perin J, Mulick A, Yeung D, et al. Global, regional, and national causes of under-5 mortality in 2000-19:an updated systematic analysis with implications for the sustainable development goals[J]. Lancet Child Adolesc Health, 2022, 6(2):106-115. DOI:10.1016/S2352-4642(21)00311-4.
[2]郑皓，陈小萍，周海健，等.血流感染病原菌分离富集技术研究进展[J].疾病监测，2025,40(9):1182-1186. DOI:10.3784/jbjc.202504090239.
[3]Shaikh KJ, Osio VA, Leeflang MM, et al. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children[J]. Cochrane Database Syst Rev, 2020,9(9):CD009185. DOI:10.1002/14651858.CD009185.pub2.
[4]Vassiliou AG, Zacharis A, Vrettou CS, et al. Comparison of the mortality prediction value of soluble urokinase plasminogen activator receptor(suPAR)in COVID-19 and sepsis[J]. Diagnostics(Basel),2022, 12(5):1261. DOI:10.3390/diagnostics12051261.
[5]Rasmussen LJH, Petersen JEV, Eugen-olsen J. Soluble urokinase plasminogen activator receptor(suPAR)as a biomarker of systemic chronic inflammation[J]. Front Immunol, 2021, 12:780641. DOI:10.3389/fimmu.2021.780641.
[6]Lv T, Zhao Y, Jiang X, et al. uPAR:an essential factor for tumor development[J]. J Cancer, 2021, 12(23):7026-7040. DOI:10.7150/jca.62281.
[7]Manfredi M, Van Hoovels L, Benucci M, et al. Soluble urokinase plasminogen activator receptor(suPAR)in autoimmune rheumatic and non rheumatic diseases[J]. J Pers Med, 2023, 13(4):688. DOI:10.3390/jpm13040688.
[8]Sudhini YR, Wei C, Reiser J. suPAR:an inflammatory mediator for kidneys[J]. Kidney Dis(Basel), 2022, 8(4):265-274. DOI:10.1159/000524965.
[9]Montecillo J, Pirker T, Pemberton C, et al. suPAR in cardiovascular disease[J]. Adv Clin Chem, 2024, 121:89-131. DOI:10.1016/bs.acc.2024.04.005.
[10]许春华，郑灵玲.涎液化糖链抗原-6 、乳酸脱氢酶、血清淀粉样蛋白A及白细胞介素-6水平与儿童病毒性肺炎严重程度相关性研究[J].传染病信息，2025,38(3):230-234. DOI:10.3969/j.issn.1007-8134.2025.03.005.
[11]王玉娇，董旭，林秀云，等.细胞免疫指标及免疫球蛋白与儿童肺炎支原体肺炎严重程度的关系[J].传染病信息，2026,39(1):70-74. DOI:10.3969/j.issn.1007-8134.2026.01.011.
[12]Tsoumani E, Carter JA, Salomonsson S, et al. Clinical, economic,and humanistic burden of community acquired pneumonia in Europe:a systematic literature review[J]. Expert Rev Vaccines, 2023,22(1):876-884. DOI:10.1080/14760584.2023.2261785.
[13]El-Mekkawy MS, Soliman SE, Saleh NY. Soluble urokinase plasminogen activator receptor:a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia[J]. Turk J Pediatr, 2022,64(1):98-109. DOI:10.24953/turkjped.2021.4321.
[14]Saleh NY, Soliman SE, Aboukoura MA, et al. Role of soluble urokinase plasminogen activator receptor in critically ill children with hospital-acquired pneumonia:an observational study in hospital with controls[J]. BMJ Paediatr Open, 2024, 8(1):e002395. DOI:10.1136/bmjpo-2023-002395.
[15]Wrotek A, Pawlik K, Jackowska T. Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children[J]. Adv Exp Med Biol, 2013, 788:329-334. DOI:10.1007/978-94-007-6627-3_44.
[16]Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor:an indicator of pneumonia severity in children[J].Adv Exp Med Biol, 2015, 835:1-7. DOI:10.1007/5584_2014_40.
[17]余菲菲，朱晓萍，龙梅，等.血清suPAR、PCT、CRP水平在小儿重症肺炎鉴别诊断中的效能分析[J].现代生物医学进展，2021,21(21):4104-4107+4099. DOI:10.13241/j.cnki.pmb.2021.21.022.
[18]余菲菲，朱晓萍，龙梅，等.重症肺炎患儿suPAR水平对比分析及与影像学表现的相关性[J].现代生物医学进展，2021,21(22):4344-4347+4362. DOI:10.13241/j.cnki.pmb.2021.22.030.
[19]Çitlenbik H, Ulusoy E, Er A, et al. Levels of soluble urokinase plasminogen activator receptor in pediatric lower respiratory tract infections[J]. Pediatr Allergy Immunol Pulmonol, 2019, 32(3):121-127.DOI:10.1089/ped.2018.0982.
[20]姚欢迎，马兰，郭平，等.血清可溶性尿激酶型纤溶酶原激活物受体在儿童下呼吸道感染中的表达及临床意义[J].医学研究杂志，2021,50(2):83-85+32. DOI:10.11969/j.issn.1673-548X.2021.02.019.
[21]Louka M, Tatsi EB, Vassiliu S, et al. The soluble urokinase plasminogen activator receptor as a severity biomarker in children with acute COVID-19 or multisystem inflammatory syndrome[J]. Pediatr Infect Dis J, 2024, 43(5):477-482. DOI:10.1097/INF.0000000000004244.
[22]Ashley EA, Poespoprodjo JR. Treatment and prevention of malaria in children[J]. Lancet Child Adolesc Health, 2020, 4(10):775-789. DOI:10.1016/S2352-4642(20)30127-9.
[23]Perch M, Kofoed P, Fischer TK, et al. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection[J]. Parasite Immunol, 2004, 26(5):207-211. DOI:10.1111/j.0141-9838.2004.00695.x.
[24]Ostrowski SR, Ullum H, Goka BQ, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome[J]. J Infect Dis, 2005, 191(8):1331-1341. DOI:10.1086/428854.
[25]Stefanova V, Ngai M, Weckman AM, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic marker of Ugandan children at risk of severe and fatal malaria[J]. Clin Infect Dis, 2023,76(3):e1079-e1086. DOI:10.1093/cid/ciac457.
[26]Tahar R, Albergaria C, Zeghidour N, et al. Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children[J]. Malar J, 2016, 15:337.DOI:10.1186/s12936-016-1378-3.
[27]Tornyigah B, Blankson SO, Adamou R, et al. Specific combinations of inflammatory, angiogenesis and vascular integrity biomarkers are associated with clinical severity, coma and mortality in Beninese children with Plasmodium falciparum malaria[J]. Diagnostics(Basel),2022, 12(2):524. DOI:10.3390/diagnostics12020524.
[28]Schlapbach LJ, Watson RS, Sorce LR, et al. International consensus criteria for pediatric sepsis and septic shock[J]. Jama, 2024,331(8):665-674. DOI:10.1001/jama.2024.0179.
[29]Siahanidou T, Margeli A, Tsirogianni C, et al. Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis:a prospective study[J]. Mediators Inflamm, 2014, 2014:375702. DOI:10.1155/2014/375702.
[30]高东培，李凤艳，谢垒，等.脓毒症患儿血清可溶性髓样细胞触发受体-1、可溶性尿激酶型纤溶酶原激活物受体变化的意义[J].中华实用儿科临床杂志，2015,30(6):433-437. DOI:10.3760/cma.j.issn.2095-428X.2015.06.009.
[31]魏婷婷，吴奎，杨湘峰，等.脓毒症患儿sTREM-1、suPAR、Cor、IL-IR1及APC的变化及其意义[J].中国妇幼卫生杂志，2018,9(3):31-35. DOI:10.19757/j.cnki.issn1674-7763.2018.03.009.
[32]Turan C, Yurtseven A, Ozkaya PY, et al. The role of soluble urokinase plasminogen activator receptor(suPAR)as an early indicator of mortality in pediatric septic shock[J]. J Clin Lab Anal, 2024,38(9):e25040. DOI:10.1002/jcla.25040.
[33]El-Mekkawy MS, Saleh NY, Sonbol AA. Soluble urokinase plasminogen activator receptor:a new biomarker in the pediatric intensive care unit[J]. Indian J Pediatr, 2016, 83(7):661-669. DOI:10.1007/s12098-016-2063-9.
[34]Xu J, Chen J, Li M, et al. Utility of plasma suPAR to identify AKI and sepsis associated AKI in critically ill children[J]. iScience, 2024,27(11):111247. DOI:10.1016/j.isci.2024.111247.
[35]Delebarre M, Gonzales F, Behal H, et al. Decision-tree derivation and external validation of a new clinical decision rule(DISCERN-FN)to predict the risk of severe infection during febrile neutropenia in children treated for cancer[J]. Lancet Child Adolesc Health, 2022,6(4):260-268. DOI:10.1016/S2352-4642(21)00337-0.
[36]Sirinoglu M, Soysal A, Karaaslan A, et al. The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia[J]. Pediatr Hematol Oncol, 2016, 33(3):200-208. DOI:10.3109/08880018.2016.1155100.
[37]占甘伟，彭娜.可溶性尿激酶型纤溶酶原激活物受体对发热性中性粒细胞减少症的诊断价值[J].临床血液学杂志，2018,31(4):257-261. DOI:10.13201/j.issn.1004-2806-b.2018.04.003.
[38]Skottrup PD, Dahlén G, Baelum V, et al. Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents[J]. Eur J Oral Sci, 2018, 126(4):292-299. DOI:10.1111/eos.12424.
[39]El-Patal MA, Khalil MA, Shipl W, et al. Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects[J]. BMC Oral Health, 2022, 22(1):436. DOI:10.1186/s12903-022-02478-7.
[40]Ostergaard C, Benfield T, Lundgren JD, et al. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome[J]. Scand J Infect Dis, 2004, 36(1):14-19. DOI:10.1080/00365540310017366.
[41]TzanakakiI G, Paparoupa M, Kyprianou M, et al. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(6):1157-1162. DOI:10.1007/s10096-011-1423-7.
[42]Wittenhagen P, Andersen JB, Hansen A, et al. Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection[J]. Biomark Insights, 2011, 6:79-82. DOI:10.4137/BMI.S6876.
[43]Jaganath D, Beaudry J, Salazar-Austin N. Tuberculosis in Children[J]. Infect Dis Clin North Am, 2022, 36(1):49-71. DOI:10.1016/j.idc.2021.11.008.
[44]Olivianto E, Sudarwati S, Nataprawira HM. Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis[J]. Int J Mycobacteriol, 2019, 8(3):262-266. DOI:10.4103/ijmy.ijmy_52_19.
[45]牟娜，李凤，安超，等.脐带血sTREM-1、SuPAR、pro-ADM检测诊断未足月胎膜早破新生儿细菌感染的价值[J].中华医院感染学杂志，2020,30(18):2821-2824. DOI:10.11816/cn.ni.2020-192569.
基本信息:
中图分类号:R725.1
引用信息:
[1]王玉娇,董旭,孙玉,等.可溶性尿激酶型纤溶酶原激活物受体在儿童感染性疾病中的应用研究进展[J].传染病信息,2026,39(03):322-328.
基金信息:
军委后勤保障部卫生局面上项目（21JSZ05）; 军队护理创新与培育专项计划项目（21HL029）
2026-06-30
2026-06-30